LEONABIO INC (LONA) Stock Price, Forecast & Analysis
NASDAQ:LONA • US04746L2034
LONA Key Statistics, Chart & Performance
The current stock price of LONA is 4.39 USD. In the past month the price decreased by -28.03%.
LONA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LONA.
LONA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LONA. While LONA seems to be doing ok healthwise, there are quite some concerns on its profitability.
LONA Financial Highlights
Over the last trailing twelve months LONA reported a non-GAAP Earnings per Share(EPS) of -9.68. The EPS increased by 66.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.61% | ||
| ROE | -140.83% | ||
| Debt/Equity | 0 |
LONA Forecast & Estimates
7 analysts have analysed LONA and the average price target is 4.08 USD. This implies a price decrease of -7.06% is expected in the next year compared to the current price of 4.39.
LONA Ownership
LONA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.87 | 979.461B | ||
| JNJ | JOHNSON & JOHNSON | 20.89 | 586.255B | ||
| MRK | MERCK & CO. INC. | 22.47 | 301.739B | ||
| PFE | PFIZER INC | 9.11 | 155.618B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.92 | 122.858B | ||
| ZTS | ZOETIS INC | 18.28 | 55.333B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.212B | ||
| VTRS | VIATRIS INC | 6.22 | 18.129B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.78 | 12.352B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.82 | 9.24B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LONA
Company Profile
LeonaBio, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
Company Info
LEONABIO INC
18706 North Creek Parkway, Suite 104
Bothell WASHINGTON US
Employees: 26
Phone: 14256208501
LEONABIO INC / LONA FAQ
What does LEONABIO INC do?
LeonaBio, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
What is the stock price of LEONABIO INC today?
The current stock price of LONA is 4.39 USD. The price increased by 1.15% in the last trading session.
Does LEONABIO INC pay dividends?
LONA does not pay a dividend.
What is the ChartMill rating of LEONABIO INC stock?
LONA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists LONA stock?
LONA stock is listed on the Nasdaq exchange.
Would investing in LEONABIO INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LONA.
What is the market capitalization of LONA stock?
LEONABIO INC (LONA) has a market capitalization of 17.30M USD. This makes LONA a Nano Cap stock.